surmount trials tirzepatide SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants Surmount Press Briefing #ADA2022

These studies consistently show that semaglutide reduces body weight, improves cardiovascular outcomes, and lowers hemoglobin A1c in people with type 2 diabetesregardless of its source

The MIC-1/GDF15GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases

Abbreviations A, amyloid protein

Anti-inflammatory effects from BPC-157 may manifest within 1-3 days as cytokine levels decrease

MARCoNS can be useful but there is disagreement in terms of which patients seem to benefit from this

Yes, tirzepatide can increase energy levels for many people, but the effect is not immediate for everyone